Breaking News Instant updates and real-time market news.

AUPH

Aurinia Pharmaceuticals

$5.47

0.09 (1.67%)

16:10
08/09/18
08/09
16:10
08/09/18
16:10

Aurinia Pharmaceuticals reports Q2 EPS (19c), consensus (15c)

Reports Q2 licensing revenue $29,000, consensus $50,000. "We are excited to announce that the AURORA Phase III trial in lupus nephritis is running ahead of schedule and we now anticipate completing enrollment in early Q4 2018. We are extremely pleased with the trial's progress thus far and having patients roll over into the AURORA 2 extension study reinforces our confidence in the program", said Richard Glickman, Aurinia's CEO and Chairman of the Board. "Our clinical team continues to deliver on our important milestones with the Phase II trials in FSGS and Dry Eye now initiated. We are well-capitalized into 2020 and look forward to an eventful second half of the year."

  • 09

    Aug

AUPH Aurinia Pharmaceuticals
$5.47

0.09 (1.67%)

10/06/17
GHSC
10/06/17
INITIATION
Target $10
GHSC
Buy
Aurinia Pharmaceuticals initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Aurinia Pharmaceuticals with a Buy and $10 price target. The analyst said Aurinia is focused on advancing voclosporin, an investigational drug that could be the first treatment specifically approved in the US for active lupus nephritis. Bernardino believes shares could be range-bound near-term, following recent strength, through the initial stage of the ongoing AURORA Phase III clinical trial.
10/30/17
HCWC
10/30/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $12 after the company at its recent analyst day announced plans to expand voclosporin development to include focal segmental glomerulosclerosis and minimal change disease. The analyst maintains a Buy rating on the shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $9
RBCM
Outperform
Aurinia Pharmaceuticals initiated with an Outperform at RBC Capital
RBC Capital analyst Douglas Miehm initiated Aurinia Pharmaceuticals with an Outperform rating and a price target of $9. The analyst says the stock represents an "attractive opportunity with upside" based on the Phase 3 study of its lupus nephritis drug voclosporin, which "has potential to become the first FDA-approved treatment for the disease".
03/16/18
CANT
03/16/18
NO CHANGE
Target $16
CANT
Overweight
Aurinia price target raised to $16 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $16 citing a reduction of the company's estimated tax rate to 21% from 35% following its Q4 results. Aurinia remains on track to enroll its Phase 3 Aurora study in Q4 and to initiate studies to advance its pipeline indications for voclosporin in Q2, Piros tells investors in a research note. He reiterates an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

TXN

Texas Instruments

$109.81

-0.25 (-0.23%)

05:40
09/25/18
09/25
05:40
09/25/18
05:40
Initiation
Texas Instruments initiated  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIMO

Silicon Motion

$54.17

0.33 (0.61%)

05:40
09/25/18
09/25
05:40
09/25/18
05:40
Initiation
Silicon Motion initiated  »

Silicon Motion initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$73.59

-0.11 (-0.15%)

05:40
09/25/18
09/25
05:40
09/25/18
05:40
Initiation
Qualcomm initiated  »

Qualcomm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ON

ON Semiconductor

$19.11

-0.035 (-0.18%)

05:39
09/25/18
09/25
05:39
09/25/18
05:39
Initiation
ON Semiconductor initiated  »

ON Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

NVDA

Nvidia

$265.72

2.28 (0.87%)

05:39
09/25/18
09/25
05:39
09/25/18
05:39
Initiation
Nvidia initiated  »

Nvidia initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 10

    Dec

MXIM

Maxim Integrated

$59.74

0.23 (0.39%)

05:39
09/25/18
09/25
05:39
09/25/18
05:39
Initiation
Maxim Integrated initiated  »

Maxim Integrated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCHP

Microchip

$82.29

-0.45 (-0.54%)

05:37
09/25/18
09/25
05:37
09/25/18
05:37
Initiation
Microchip initiated  »

Microchip initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.91

0.27 (0.58%)

05:37
09/25/18
09/25
05:37
09/25/18
05:37
Initiation
Intel initiated  »

Intel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AMD

AMD

$32.62

1.61 (5.19%)

05:37
09/25/18
09/25
05:37
09/25/18
05:37
Initiation
AMD initiated  »

AMD initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADI

Analog Devices

$95.01

0.45 (0.48%)

05:36
09/25/18
09/25
05:36
09/25/18
05:36
Initiation
Analog Devices initiated  »

Analog Devices initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HP

Helmerich & Payne

$67.61

0.34 (0.51%)

05:34
09/25/18
09/25
05:34
09/25/18
05:34
Upgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHXM

DHX Media

$1.08

-0.11 (-9.24%)

, SNE

Sony

$56.86

-0.175 (-0.31%)

05:34
09/25/18
09/25
05:34
09/25/18
05:34
Hot Stocks
DHX Media concludes strategic review »

DHX Media (DHXM)…

DHXM

DHX Media

$1.08

-0.11 (-9.24%)

SNE

Sony

$56.86

-0.175 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ASC

Ardmore Shipping

$6.90

-0.05 (-0.72%)

05:33
09/25/18
09/25
05:33
09/25/18
05:33
Upgrade
Ardmore Shipping rating change  »

Ardmore Shipping upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

CENT

Central Garden & Pet

$38.28

-0.95 (-2.42%)

05:30
09/25/18
09/25
05:30
09/25/18
05:30
Initiation
Central Garden & Pet initiated  »

Central Garden & Pet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFIN

Donnelley Financial Solutions

$20.78

0.19 (0.92%)

05:27
09/25/18
09/25
05:27
09/25/18
05:27
Downgrade
Donnelley Financial Solutions rating change  »

Donnelley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$207.30

2.25 (1.10%)

05:26
09/25/18
09/25
05:26
09/25/18
05:26
Hot Stocks
Amgen announces approval for Blincyto in Japan »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 17

    Oct

  • 22

    Oct

  • 09

    Nov

SAIC

SAIC

$78.88

-0.59 (-0.74%)

, EGL

Engility

$35.14

-0.12 (-0.34%)

05:23
09/25/18
09/25
05:23
09/25/18
05:23
Upgrade
SAIC, Engility rating change  »

SAIC upgraded to Buy from…

SAIC

SAIC

$78.88

-0.59 (-0.74%)

EGL

Engility

$35.14

-0.12 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLR

Digital Realty

$115.95

-5.055 (-4.18%)

05:19
09/25/18
09/25
05:19
09/25/18
05:19
Syndicate
Digital Realty 8.5M share Secondary priced at $113.00 »

BofA/Merrill and Citi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 04

    Oct

  • 22

    Oct

  • 25

    Sep

SQ

Square

$86.06

0.75 (0.88%)

, FB

Facebook

$165.40

2.5 (1.53%)

05:18
09/25/18
09/25
05:18
09/25/18
05:18
Recommendations
Square, Facebook, Alphabet, Alphabet Class A, Amazon.com, Netflix analyst commentary  »

Square price target…

SQ

Square

$86.06

0.75 (0.88%)

FB

Facebook

$165.40

2.5 (1.53%)

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

NFLX

Netflix

$369.70

8.71 (2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 16

    Oct

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 13

    Nov

  • 26

    Nov

  • 03

    Mar

VIOT

Viomi Technology

$0.00

(0.00%)

05:18
09/25/18
09/25
05:18
09/25/18
05:18
Syndicate
Viomi Technology 11.4M share IPO priced at $9.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

VCTR

Victory Capital

$9.50

0.45 (4.97%)

05:12
09/25/18
09/25
05:12
09/25/18
05:12
Upgrade
Victory Capital rating change  »

Victory Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

  • 10

    Oct

IRET

Investors Real Estate

$5.58

-0.03 (-0.53%)

05:11
09/25/18
09/25
05:11
09/25/18
05:11
Upgrade
Investors Real Estate rating change  »

Investors Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCCI

Heritage-Crystal Clean

$20.40

-0.15 (-0.73%)

05:10
09/25/18
09/25
05:10
09/25/18
05:10
Upgrade
Heritage-Crystal Clean rating change  »

Heritage-Crystal Clean…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 01

    Oct

GHDX

Genomic Health

$70.84

1.65 (2.38%)

, LH

LabCorp

$169.54

-2.46 (-1.43%)

05:09
09/25/18
09/25
05:09
09/25/18
05:09
Recommendations
Genomic Health, LabCorp, Myriad Genetics, Natera, Quest Diagnostics analyst commentary  »

Piper sees early winners…

GHDX

Genomic Health

$70.84

1.65 (2.38%)

LH

LabCorp

$169.54

-2.46 (-1.43%)

MYGN

Myriad Genetics

$46.91

0.64 (1.38%)

NTRA

Natera

$23.83

-0.35 (-1.45%)

DGX

Quest Diagnostics

$107.61

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 06

    Nov

  • 27

    Nov

WK

Workiva

$37.20

0.65 (1.78%)

05:08
09/25/18
09/25
05:08
09/25/18
05:08
Upgrade
Workiva rating change  »

Workiva upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.